rss
Br J Ophthalmol 2004;88:1226-1227 doi:10.1136/bjo.2004.045997
  • Letter

Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage?

  1. B R Davies
  1. Hull and East Yorkshire Eye Hospital, Fountain Street, Hull HU3 2JZ, UK
  1. Correspondence to: B R Davies Hull and East Yorkshire Eye Hospital, Fountain Street, Hull HU3 2JZ, UK; bryn.dukonline.co.uk
  • Accepted 11 March 2004

Clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi) is a thienopyridine with antiplatelet effects caused by its inhibition of ADP mediated platelet aggregation pathways.1 Both aspirin and clopidogrel have established benefits in the secondary prevention of fatal and non-fatal coronary and cerebrovascular events.1,2 The CURE study has concluded that combining low dose aspirin and clopidogrel in patients with acute coronary syndromes results in additional improvements in outcome over aspirin alone.3 We can therefore expect increasing numbers of ophthalmic patients who have been started on this combined treatment (“COM”).

Departmental concerns were raised by experience with a 76 year old normotensive patient who was on COM. He …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.